Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions...
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in...
Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.035 | 0.04 | 0.035 | 9841 | 0.03661613 | CS |
| 4 | 0 | 0 | 0.035 | 0.045 | 0.03 | 72180 | 0.03461485 | CS |
| 12 | 0.005 | 16.6666666667 | 0.03 | 0.045 | 0.025 | 120526 | 0.03374928 | CS |
| 26 | -0.005 | -12.5 | 0.04 | 0.045 | 0.025 | 106522 | 0.0349891 | CS |
| 52 | 0.005 | 16.6666666667 | 0.03 | 0.06 | 0.025 | 129545 | 0.0370956 | CS |
| 156 | -0.065 | -65 | 0.1 | 0.18 | 0.025 | 159405 | 0.06104684 | CS |
| 260 | -1.095 | -96.9026548673 | 1.13 | 1.6 | 0.025 | 164120 | 0.27041394 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
